JP2021500349A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021500349A5 JP2021500349A5 JP2020522016A JP2020522016A JP2021500349A5 JP 2021500349 A5 JP2021500349 A5 JP 2021500349A5 JP 2020522016 A JP2020522016 A JP 2020522016A JP 2020522016 A JP2020522016 A JP 2020522016A JP 2021500349 A5 JP2021500349 A5 JP 2021500349A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- composition
- composition according
- dose
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 91
- 238000000034 method Methods 0.000 claims description 76
- 206010028980 Neoplasm Diseases 0.000 claims description 51
- 239000003795 chemical substances by application Substances 0.000 claims description 34
- 230000000638 stimulation Effects 0.000 claims description 27
- 206010033128 Ovarian cancer Diseases 0.000 claims description 22
- 239000002246 antineoplastic agent Substances 0.000 claims description 20
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 20
- 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 claims description 16
- 210000001995 reticulocyte Anatomy 0.000 claims description 16
- 229940127089 cytotoxic agent Drugs 0.000 claims description 13
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical group [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 12
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 11
- 239000012661 PARP inhibitor Substances 0.000 claims description 11
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 claims description 11
- 239000011724 folic acid Substances 0.000 claims description 11
- 229960000304 folic acid Drugs 0.000 claims description 11
- 235000019152 folic acid Nutrition 0.000 claims description 11
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims description 9
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims description 9
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims description 9
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims description 9
- 239000003112 inhibitor Substances 0.000 claims description 9
- 239000002525 vasculotropin inhibitor Substances 0.000 claims description 9
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 claims description 8
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 claims description 8
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 8
- 230000037452 priming Effects 0.000 claims description 8
- 238000004458 analytical method Methods 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 6
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims description 6
- 229910052697 platinum Inorganic materials 0.000 claims description 6
- 208000007690 Brenner tumor Diseases 0.000 claims description 4
- 206010073258 Brenner tumour Diseases 0.000 claims description 4
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims description 4
- 201000000274 Carcinosarcoma Diseases 0.000 claims description 4
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 4
- 102000001554 Hemoglobins Human genes 0.000 claims description 4
- 108010054147 Hemoglobins Proteins 0.000 claims description 4
- 101000955067 Homo sapiens WAP four-disulfide core domain protein 2 Proteins 0.000 claims description 4
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 4
- 102100038965 WAP four-disulfide core domain protein 2 Human genes 0.000 claims description 4
- 108010081667 aflibercept Proteins 0.000 claims description 4
- 210000004369 blood Anatomy 0.000 claims description 4
- 239000008280 blood Substances 0.000 claims description 4
- 210000004027 cell Anatomy 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 210000003743 erythrocyte Anatomy 0.000 claims description 4
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 4
- 229960005277 gemcitabine Drugs 0.000 claims description 4
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 claims description 4
- 238000003384 imaging method Methods 0.000 claims description 4
- 208000022669 mucinous neoplasm Diseases 0.000 claims description 4
- PCHKPVIQAHNQLW-CQSZACIVSA-N niraparib Chemical compound N1=C2C(C(=O)N)=CC=CC2=CN1C(C=C1)=CC=C1[C@@H]1CCCNC1 PCHKPVIQAHNQLW-CQSZACIVSA-N 0.000 claims description 4
- 229950011068 niraparib Drugs 0.000 claims description 4
- 229960001592 paclitaxel Drugs 0.000 claims description 4
- WBXPDJSOTKVWSJ-ZDUSSCGKSA-L pemetrexed(2-) Chemical compound C=1NC=2NC(N)=NC(=O)C=2C=1CCC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 WBXPDJSOTKVWSJ-ZDUSSCGKSA-L 0.000 claims description 4
- 208000026087 primary peritoneal tumor Diseases 0.000 claims description 4
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 4
- 230000003211 malignant effect Effects 0.000 claims description 3
- 108010058566 130-nm albumin-bound paclitaxel Proteins 0.000 claims description 2
- -1 Abraxane®) Chemical compound 0.000 claims description 2
- 108010012934 Albumin-Bound Paclitaxel Proteins 0.000 claims description 2
- 102100026882 Alpha-synuclein Human genes 0.000 claims description 2
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 2
- XXPXYPLPSDPERN-UHFFFAOYSA-N Ecteinascidin 743 Natural products COc1cc2C(NCCc2cc1O)C(=O)OCC3N4C(O)C5Cc6cc(C)c(OC)c(O)c6C(C4C(S)c7c(OC(=O)C)c(C)c8OCOc8c37)N5C XXPXYPLPSDPERN-UHFFFAOYSA-N 0.000 claims description 2
- 102000003951 Erythropoietin Human genes 0.000 claims description 2
- 108090000394 Erythropoietin Proteins 0.000 claims description 2
- 101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 claims description 2
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims description 2
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 claims description 2
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 claims description 2
- 101000652359 Homo sapiens Spermatogenesis-associated protein 2 Proteins 0.000 claims description 2
- 239000002138 L01XE21 - Regorafenib Substances 0.000 claims description 2
- 206010027476 Metastases Diseases 0.000 claims description 2
- 229930012538 Paclitaxel Natural products 0.000 claims description 2
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims description 2
- 229940028652 abraxane Drugs 0.000 claims description 2
- 229960002833 aflibercept Drugs 0.000 claims description 2
- 229940110282 alimta Drugs 0.000 claims description 2
- 229960000473 altretamine Drugs 0.000 claims description 2
- 208000007502 anemia Diseases 0.000 claims description 2
- 229940120638 avastin Drugs 0.000 claims description 2
- 229960000397 bevacizumab Drugs 0.000 claims description 2
- 229940088954 camptosar Drugs 0.000 claims description 2
- 229960004562 carboplatin Drugs 0.000 claims description 2
- 190000008236 carboplatin Chemical compound 0.000 claims description 2
- HWGQMRYQVZSGDQ-HZPDHXFCSA-N chembl3137320 Chemical compound CN1N=CN=C1[C@H]([C@H](N1)C=2C=CC(F)=CC=2)C2=NNC(=O)C3=C2C1=CC(F)=C3 HWGQMRYQVZSGDQ-HZPDHXFCSA-N 0.000 claims description 2
- 229960004316 cisplatin Drugs 0.000 claims description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 2
- 229960004397 cyclophosphamide Drugs 0.000 claims description 2
- 230000007423 decrease Effects 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 229960003668 docetaxel Drugs 0.000 claims description 2
- 229960004679 doxorubicin Drugs 0.000 claims description 2
- 208000023965 endometrium neoplasm Diseases 0.000 claims description 2
- 229940105423 erythropoietin Drugs 0.000 claims description 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 2
- 229940051306 eylea Drugs 0.000 claims description 2
- 102000006815 folate receptor Human genes 0.000 claims description 2
- 108020005243 folate receptor Proteins 0.000 claims description 2
- 125000003929 folic acid group Chemical group 0.000 claims description 2
- 229940020967 gemzar Drugs 0.000 claims description 2
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 claims description 2
- 229940090411 ifex Drugs 0.000 claims description 2
- 229960001101 ifosfamide Drugs 0.000 claims description 2
- 229960004768 irinotecan Drugs 0.000 claims description 2
- 230000004060 metabolic process Effects 0.000 claims description 2
- 230000009401 metastasis Effects 0.000 claims description 2
- FAQDUNYVKQKNLD-UHFFFAOYSA-N olaparib Chemical compound FC1=CC=C(CC2=C3[CH]C=CC=C3C(=O)N=N2)C=C1C(=O)N(CC1)CCN1C(=O)C1CC1 FAQDUNYVKQKNLD-UHFFFAOYSA-N 0.000 claims description 2
- 229960000572 olaparib Drugs 0.000 claims description 2
- 229960005079 pemetrexed Drugs 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims description 2
- 238000012292 receptor occupancy assay Methods 0.000 claims description 2
- 229960004836 regorafenib Drugs 0.000 claims description 2
- FNHKPVJBJVTLMP-UHFFFAOYSA-N regorafenib Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=C(F)C(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 FNHKPVJBJVTLMP-UHFFFAOYSA-N 0.000 claims description 2
- 229950004707 rucaparib Drugs 0.000 claims description 2
- INBJJAFXHQQSRW-STOWLHSFSA-N rucaparib camsylate Chemical compound CC1(C)[C@@H]2CC[C@@]1(CS(O)(=O)=O)C(=O)C2.CNCc1ccc(cc1)-c1[nH]c2cc(F)cc3C(=O)NCCc1c23 INBJJAFXHQQSRW-STOWLHSFSA-N 0.000 claims description 2
- 229920006395 saturated elastomer Polymers 0.000 claims description 2
- RCINICONZNJXQF-XAZOAEDWSA-N taxol® Chemical compound O([C@@H]1[C@@]2(CC(C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3(C21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-XAZOAEDWSA-N 0.000 claims description 2
- 229940063683 taxotere Drugs 0.000 claims description 2
- 229960000303 topotecan Drugs 0.000 claims description 2
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims description 2
- PKVRCIRHQMSYJX-AIFWHQITSA-N trabectedin Chemical compound C([C@@]1(C(OC2)=O)NCCC3=C1C=C(C(=C3)O)OC)S[C@@H]1C3=C(OC(C)=O)C(C)=C4OCOC4=C3[C@H]2N2[C@@H](O)[C@H](CC=3C4=C(O)C(OC)=C(C)C=3)N(C)[C@H]4[C@@H]21 PKVRCIRHQMSYJX-AIFWHQITSA-N 0.000 claims description 2
- JNAHVYVRKWKWKQ-CYBMUJFWSA-N veliparib Chemical compound N=1C2=CC=CC(C(N)=O)=C2NC=1[C@@]1(C)CCCN1 JNAHVYVRKWKWKQ-CYBMUJFWSA-N 0.000 claims description 2
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 claims description 2
- 229940053867 xeloda Drugs 0.000 claims description 2
- 229940004212 yondelis Drugs 0.000 claims description 2
- 239000002269 analeptic agent Substances 0.000 claims 1
- 210000004602 germ cell Anatomy 0.000 claims 1
- 238000009169 immunotherapy Methods 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 208000028467 sex cord-stromal tumor Diseases 0.000 claims 1
- 229950011257 veliparib Drugs 0.000 claims 1
- 230000003442 weekly effect Effects 0.000 claims 1
- 230000036039 immunity Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 208000016848 malignant germ cell tumor Diseases 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022186406A JP2023018062A (ja) | 2017-10-18 | 2022-11-22 | 抗ｃｄ４７剤ベースの卵巣癌療法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762573835P | 2017-10-18 | 2017-10-18 | |
| US62/573,835 | 2017-10-18 | ||
| PCT/US2018/056441 WO2019079548A1 (en) | 2017-10-18 | 2018-10-18 | OVARIAN CANCER THERAPY BASED ON ANTI-CD47 AGENT |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022186406A Division JP2023018062A (ja) | 2017-10-18 | 2022-11-22 | 抗ｃｄ４７剤ベースの卵巣癌療法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021500349A JP2021500349A (ja) | 2021-01-07 |
| JP2021500349A5 true JP2021500349A5 (enExample) | 2021-10-07 |
| JP7308191B2 JP7308191B2 (ja) | 2023-07-13 |
Family
ID=64267915
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020522016A Active JP7308191B2 (ja) | 2017-10-18 | 2018-10-18 | 抗ｃｄ４７剤ベースの卵巣癌療法 |
| JP2022186406A Pending JP2023018062A (ja) | 2017-10-18 | 2022-11-22 | 抗ｃｄ４７剤ベースの卵巣癌療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022186406A Pending JP2023018062A (ja) | 2017-10-18 | 2022-11-22 | 抗ｃｄ４７剤ベースの卵巣癌療法 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11802153B2 (enExample) |
| EP (2) | EP4177270B1 (enExample) |
| JP (2) | JP7308191B2 (enExample) |
| KR (1) | KR102776457B1 (enExample) |
| CN (2) | CN117771364A (enExample) |
| AU (1) | AU2018351006B2 (enExample) |
| CA (1) | CA3078253A1 (enExample) |
| ES (2) | ES2989007T3 (enExample) |
| PL (2) | PL4177270T3 (enExample) |
| PT (2) | PT4177270T (enExample) |
| SI (2) | SI4177270T1 (enExample) |
| WO (1) | WO2019079548A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10927173B2 (en) | 2016-01-11 | 2021-02-23 | Forty Seven, Inc. | Humanized, mouse or chimeric anti-CD47 monoclonal antibodies |
| PL4177270T3 (pl) | 2017-10-18 | 2024-11-18 | Forty Seven, Inc. | Terapia nowotworu złośliwego jajnika w oparciu o środek anty-cd47 |
| CN111699005A (zh) | 2018-02-12 | 2020-09-22 | 四十七公司 | 使用抗cd47抗体和抗cd20抗体的抗癌方案 |
| US12178803B2 (en) | 2018-09-04 | 2024-12-31 | Pfizer Inc. | CD47 blockade with PARP inhibition for disease treatment |
| CN115397853A (zh) | 2019-12-17 | 2022-11-25 | 辉瑞大药厂 | 对cd47、pd-l1具特异性的抗体及其用途 |
| JP7560038B2 (ja) * | 2020-04-06 | 2024-10-02 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 抗体製剤 |
| WO2021259902A1 (en) * | 2020-06-22 | 2021-12-30 | Morphosys Ag | Anti-tumor combination therapy comprising anti-cd19 antibody and polypeptides blocking the sirpα-cd47 innate immune checkpoint |
| CN114452403A (zh) * | 2021-02-10 | 2022-05-10 | 同润生物医药(上海)有限公司 | 一种含有双功能免疫检查点/TGFβ抑制剂的药物组合 |
| MX2023010687A (es) * | 2021-04-14 | 2023-09-22 | Akeso Biopharma Inc | Anticuerpos monoclonales anti cd47 y usos de los mismos. |
| KR20240019111A (ko) * | 2021-06-10 | 2024-02-14 | 오노 야꾸힝 고교 가부시키가이샤 | Cd47 저해 물질, 면역 체크포인트 저해 물질 및 표준 요법의 병용에 의한 암 치료법 |
| CN115245516A (zh) * | 2021-12-31 | 2022-10-28 | 郑州大学第一附属医院 | 一种抗卵巢癌肿瘤药物联用方法、体外和体内验证方法 |
| US20250228938A1 (en) * | 2022-03-08 | 2025-07-17 | Whitehead Institute For Biomedical Research | The combination of macrophage-directed immunotherapy and targeted agents for treatment of cancer |
| TWI876305B (zh) * | 2022-04-05 | 2025-03-11 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5547656B2 (ja) | 2008-01-15 | 2014-07-16 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | Ｃｄ４７によって媒介される食作用を操作するための方法 |
| SI2477648T1 (sl) | 2009-09-15 | 2022-09-30 | The Board Of Trustees Of The Leland Stanford Junior University | Sinergijska terapija proti CD47 za krvne rake |
| US9151760B2 (en) | 2009-09-29 | 2015-10-06 | The Board Of Trustees Of The Leland Stanford Junior University | Isolation and use of melanoma cancer stem cells |
| CA3138956A1 (en) | 2010-05-14 | 2011-11-17 | The Board Of Trustees Of The Leland Stanford Junior University | Humanized and chimeric monoclonal antibodies to cd47 |
| WO2012088309A1 (en) | 2010-12-21 | 2012-06-28 | The Board Of Trustees Of The Leland Stanford Junior University | Therapeutic and diagnostic methods for manipulating phagocytosis through calreticulin and low density lipoprotein-related receptor |
| AU2013209736C1 (en) | 2012-01-17 | 2017-12-14 | The Board Of Trustees Of The Leland Stanford Junior University | High affinity SIRP-alpha reagents |
| BR112015013431A2 (pt) | 2012-12-12 | 2017-11-14 | Vasculox Inc | anticorpos monoclonais ou respectivos fragmentos ligantes de antígenos, composição farmacêutica, e usos de anticorpo monoclonal ou respectivo fragmento ligante de antígenos |
| JP6426693B2 (ja) | 2013-03-15 | 2018-11-21 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 抗ｃｄ４７薬の処理上有効量を達成するための方法 |
| ES2898627T3 (es) | 2013-04-29 | 2022-03-08 | Univ Leland Stanford Junior | Uso de agentes anti-CD47 para mejorar la inmunización |
| WO2014186761A2 (en) | 2013-05-17 | 2014-11-20 | The Board Of Trustes Of The Leland Stanford Junior University | Methods for determining responsiveness to an anti-cd47 agent |
| JP6606505B2 (ja) | 2014-03-11 | 2019-11-13 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 抗ＳＩＲＰα抗体および二重特異性マクロファージ増強抗体 |
| HRP20201153T1 (hr) | 2014-08-08 | 2021-01-22 | The Board Of Trustees Of The Leland Stanford Junior University | Pd-1 sredstva visokog afiniteta i načini uporabe |
| WO2016023001A1 (en) | 2014-08-08 | 2016-02-11 | The Board Of Trustees Of The Leland Stanford Junior University | Multispecific high affinity pd-1 agents and methods of use |
| JP6678941B2 (ja) | 2014-10-07 | 2020-04-15 | イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． | 抗体−薬物コンジュゲートのネオアジュバント使用 |
| CA2959821C (en) | 2014-10-24 | 2024-10-29 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for inducing phagocytosis of MHC class I positive cells and for overcoming resistance to anti-CD47 agents/SIRPA |
| TWI595006B (zh) | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | 抗ｐｄ－１抗體類和使用彼等之方法 |
| EP4019040A1 (en) | 2015-01-21 | 2022-06-29 | The Board of Trustees of the Leland Stanford Junior University | Use of trl agonist and anti-cd47 agent to enhance phagocytosis of cancer cells |
| US10358472B2 (en) | 2015-05-06 | 2019-07-23 | The Board Of Trustees Of The Leland Stanford Junior University | High affinity CD47 analogs |
| US20180147257A1 (en) | 2015-05-22 | 2018-05-31 | The Board Of Trustees Of The Leland Stanford Junior University | Btn3a ectodomain proteins and methods of use |
| WO2017019767A1 (en) | 2015-07-27 | 2017-02-02 | Myosotis, Llc | Inhibition of CXCL12 in Cancer Immunotherapy |
| SI3341015T2 (sl) | 2015-08-26 | 2024-03-29 | The Board Of Trustees Of The Leland Stanford, Junior University | Izboljšana deplecija ciljanih celic z blokado CD47 in imunostimulatornim agonistom |
| RU2748401C2 (ru) * | 2015-09-18 | 2021-05-25 | Арч Онколоджи, Инк. | Терапевтические антитела к CD47 |
| WO2017100462A2 (en) * | 2015-12-11 | 2017-06-15 | The Board Of Trustees Of The Leland Stanford Junior University | Treatment of cancer with dual targeting of cd47 and egfr |
| BR112018013094A2 (pt) | 2015-12-28 | 2018-12-11 | Merck Patent Gmbh | combinação de inibidor de hdac e anticorpo de anti-pd-l1 para o tratamento de câncer ovariano |
| US10927173B2 (en) * | 2016-01-11 | 2021-02-23 | Forty Seven, Inc. | Humanized, mouse or chimeric anti-CD47 monoclonal antibodies |
| KR102833922B1 (ko) * | 2016-01-21 | 2025-07-15 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 면역조절제의 조합물에 의한 암의 치료 |
| CN117695387A (zh) | 2016-04-15 | 2024-03-15 | 小利兰·斯坦福大学托管委员会 | 用于确定和实现抗cd47药剂治疗癌症的治疗有效剂量的方法 |
| WO2018026600A1 (en) | 2016-08-03 | 2018-02-08 | The Board Of Trustees Of The Leland Stanford Junior University | Disrupting fc receptor engagement on macrophages enhances efficacy of anti-sirpalpha antibody therapy |
| WO2018031419A1 (en) | 2016-08-12 | 2018-02-15 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for enhancing immunogenic cross-presentation of tumor antigens |
| PL3532497T3 (pl) | 2016-10-26 | 2024-11-04 | The Board Of Trustees Of The Leland Stanford Junior University | Zmodyfikowane regiony zawiasowe immunoglobuliny dla zmniejszania hemaglutynacji |
| WO2018165015A1 (en) | 2017-03-09 | 2018-09-13 | The Board Of Trustees Of The Leland Stanford Junior University | Treatment of pediatric brain tumors with targeting of cd47 pathway |
| CA3078430A1 (en) | 2017-10-18 | 2019-04-25 | Forty Seven, Inc. | Treatment of ovarian cancer with anti-cd47 and anti-pd-l1 |
| PL4177270T3 (pl) | 2017-10-18 | 2024-11-18 | Forty Seven, Inc. | Terapia nowotworu złośliwego jajnika w oparciu o środek anty-cd47 |
| WO2019241403A1 (en) | 2018-06-13 | 2019-12-19 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for inducing phagocytosis |
| US20220091104A1 (en) | 2018-09-28 | 2022-03-24 | The Board Of Trustees Of The Leland Stanford Junior University | Analysis of polymorphisms in sirp-alpha for evaluating response to immunotherapy |
| WO2020160285A1 (en) | 2019-02-01 | 2020-08-06 | The Board Of Trustees Of The Leland Stanford Junior University | SIRPα EXPRESSION ON T CELLS IS A BIOMARKER FOR FUNCTIONAL T CELLS DURING EXHAUSTION |
| WO2020163692A1 (en) | 2019-02-08 | 2020-08-13 | The Board Of Trustees Of The Leland Stanford Junior University | Treatment of cutaneous t cell lymphoma with targeting of cd47 pathway |
-
2018
- 2018-10-18 PL PL22199536.8T patent/PL4177270T3/pl unknown
- 2018-10-18 JP JP2020522016A patent/JP7308191B2/ja active Active
- 2018-10-18 CN CN202311510416.3A patent/CN117771364A/zh active Pending
- 2018-10-18 KR KR1020207014145A patent/KR102776457B1/ko active Active
- 2018-10-18 PT PT221995368T patent/PT4177270T/pt unknown
- 2018-10-18 CN CN201880068424.8A patent/CN111247172B/zh active Active
- 2018-10-18 ES ES22199536T patent/ES2989007T3/es active Active
- 2018-10-18 CA CA3078253A patent/CA3078253A1/en active Pending
- 2018-10-18 EP EP22199536.8A patent/EP4177270B1/en active Active
- 2018-10-18 PL PL18800381.8T patent/PL3697817T3/pl unknown
- 2018-10-18 SI SI201831145T patent/SI4177270T1/sl unknown
- 2018-10-18 EP EP18800381.8A patent/EP3697817B1/en active Active
- 2018-10-18 PT PT188003818T patent/PT3697817T/pt unknown
- 2018-10-18 SI SI201830808T patent/SI3697817T1/sl unknown
- 2018-10-18 ES ES18800381T patent/ES2932286T3/es active Active
- 2018-10-18 US US16/756,673 patent/US11802153B2/en active Active
- 2018-10-18 AU AU2018351006A patent/AU2018351006B2/en active Active
- 2018-10-18 WO PCT/US2018/056441 patent/WO2019079548A1/en not_active Ceased
-
2022
- 2022-11-22 JP JP2022186406A patent/JP2023018062A/ja active Pending
-
2023
- 2023-09-27 US US18/373,655 patent/US20240150461A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021500349A5 (enExample) | ||
| Brosnan et al. | Understanding patterns of brain metastasis in breast cancer and designing rational therapeutic strategies | |
| EP2903610B1 (en) | Cancer treatments | |
| Pinto et al. | Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study) | |
| CN102223897B (zh) | 抗-vegf抗体与化学治疗联合用于治疗乳腺癌的应用 | |
| TWI619509B (zh) | 治療先前未經治療之ⅲ期或ⅳ期卵巢癌、輸卵管癌或原發性腹膜癌之卡鉑、太平洋紫杉醇與抗-vegf抗體之組合 | |
| JP2020059713A (ja) | 膠芽腫治療のための併用療法 | |
| Macaulay et al. | Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R), administered in combination with anticancer therapies to patients with advanced solid tumors | |
| Pandey et al. | Engineered nanomaterials as an effective tool for HER2+ breast cancer therapy | |
| TW200838875A (en) | Combination therapy with angiogenesis inhibitors | |
| EP3446709A1 (en) | Combination therapy for the treatment of glioblastoma | |
| Nechushtan et al. | A phase 1/2 of a combination of cetuximab and taxane for “triple negative” breast cancer patients | |
| JP2021500336A5 (enExample) | ||
| EP3553083A1 (en) | Combination therapy for the treatment of ovarian cancer | |
| JP2020506945A (ja) | がんの治療のための方法、組成物及びキット | |
| Koukourakis et al. | Targeted therapy with bevacizumab (Avastin) for metastatic colorectal cancer | |
| KR20210084560A (ko) | Pd-1/pd-l1 신호전달 억제제에 반응하지 않는 암을 치료하기 위한 방법 및 약제 | |
| EP1740182A2 (en) | Use of 5,10-methylene tetrahydrofolate for the treatment of cancer | |
| WO2012106379A1 (en) | Sensitization of cancer cells to treatment | |
| TW201109032A (en) | Anti-angiogenesis therapy for the treatment of previously treated breast cancer | |
| JP2005511663A5 (enExample) | ||
| George et al. | Selective kinase inhibition with daily imatinib intensifies toxicity of chemotherapy in patients with solid tumours | |
| Miyata et al. | Current treatment landscape for patients with non–small cell lung cancer with common EGFR mutations | |
| US20210363253A1 (en) | Use of combined treatment of pd-1 antibody and apatinib for treating triple negative breast cancer | |
| RU2774721C2 (ru) | Применение комбинированного лечения на основе антитела к PD-1 и апатиниба для лечения трижды негативного рака молочной железы |